Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-08-21
Tempus AI, Inc.
Tempus AI provides oncology and genetic testing, clinical workflow software, and de-identified data products for healthcare providers and life-science companies.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Precision oncology platform with real mix-shift upside
A fast-growing cancer diagnostics and data business is trying to graduate from premium lab economics to workflow and intelligence economics. The opportunity is real, but the rerating now depends on reimbursement conversion, MRD scale, and proof that AI can drive trusted clinical actions.

Analysis

Thesis
Tempus can compound a growing diagnostics base into a higher-value oncology intelligence layer: more testing creates more proprietary multimodal data, which improves applications, attracts pharma demand, and deepens workflow dependence. If reimbursement upgrades and MRD integration land, revenue can outgrow peer labs while mix shifts toward better margins.
Last Economy Alignment
Cheaper AI makes Tempus' data rights, workflow embeds, and clinically trusted decision tools more valuable, while diagnostics-heavy monetization limits pure software deflation. The main brake is that payers and regulators still control how fast value can be captured.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
This is a mix-shift story, not a pure volume story. The core lab business should keep growing, but the real upside comes from MRD, reimbursement-led price improvement, and turning data plus workflow into trusted clinical actions. That can support faster growth than standard diagnostics peers, yet I still assume some valuation compression as the company matures and must prove durable cash generation.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is monetization timing, not technical possibility. Tempus must convert diagnostic growth, MRD scale, and AI credibility into reimbursed pricing, higher-margin data revenue, and cash generation before dilution, leverage, or a peer-multiple reset erode the equity case. If it stays mostly a premium lab with nice software, the upside compresses sharply.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.64
It sits where cancer testing, patient data, and doctor workflow meet, so cheaper AI makes its dataset and decision tools more useful. The risk is that payers and regulators still decide how much of that usefulness can actually be monetized.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$62.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case